Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Social work-generated evidence in traumatic brain injury from 1975 to 2014: A systematic scoping review.

Mantell A, Simpson GK, Vungkhanching M, Jones KF, Strandberg T, Simonson P.

Health Soc Care Community. 2017 Aug 9. doi: 10.1111/hsc.12476. [Epub ahead of print] Review.

PMID:
28795463
2.

Pharmacokinetics and interspecies allometric scaling of ST-246, an oral antiviral therapeutic for treatment of orthopoxvirus infection.

Amantana A, Chen Y, Tyavanagimatt SR, Jones KF, Jordan R, Chinsangaram J, Bolken TC, Leeds JM, Hruby DE.

PLoS One. 2013 Apr 18;8(4):e61514. doi: 10.1371/journal.pone.0061514. Print 2013.

3.

Novel benzoxazole inhibitor of dengue virus replication that targets the NS3 helicase.

Byrd CM, Grosenbach DW, Berhanu A, Dai D, Jones KF, Cardwell KB, Schneider C, Yang G, Tyavanagimatt S, Harver C, Wineinger KA, Page J, Stavale E, Stone MA, Fuller KP, Lovejoy C, Leeds JM, Hruby DE, Jordan R.

Antimicrob Agents Chemother. 2013 Apr;57(4):1902-12. doi: 10.1128/AAC.02251-12. Epub 2013 Feb 12.

4.

A novel inhibitor of dengue virus replication that targets the capsid protein.

Byrd CM, Dai D, Grosenbach DW, Berhanu A, Jones KF, Cardwell KB, Schneider C, Wineinger KA, Page JM, Harver C, Stavale E, Tyavanagimatt S, Stone MA, Bartenschlager R, Scaturro P, Hruby DE, Jordan R.

Antimicrob Agents Chemother. 2013 Jan;57(1):15-25. doi: 10.1128/AAC.01429-12. Epub 2012 Oct 15.

5.

Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers.

Chinsangaram J, Honeychurch KM, Tyavanagimatt SR, Leeds JM, Bolken TC, Jones KF, Jordan R, Marbury T, Ruckle J, Mee-Lee D, Ross E, Lichtenstein I, Pickens M, Corrado M, Clarke JM, Frimm AM, Hruby DE.

Antimicrob Agents Chemother. 2012 Sep;56(9):4900-5. doi: 10.1128/AAC.00904-12. Epub 2012 Jul 9.

6.

Pharmacokinetic comparison of a single oral dose of polymorph form i versus form V capsules of the antiorthopoxvirus compound ST-246 in human volunteers.

Chinsangaram J, Honeychurch KM, Tyavanagimatt SR, Bolken TC, Jordan R, Jones KF, Marbury T, Lichtenstein I, Pickens M, Corrado M, Landis P, Clarke JM, Frimm AM, Hruby DE.

Antimicrob Agents Chemother. 2012 Jul;56(7):3582-6. doi: 10.1128/AAC.06090-11. Epub 2012 Apr 23.

7.

Comparison of the safety and pharmacokinetics of ST-246® after i.v. infusion or oral administration in mice, rabbits and monkeys.

Chen Y, Amantana A, Tyavanagimatt SR, Zima D, Yan XS, Kasi G, Weeks M, Stone MA, Weimers WC, Samuel P, Tan Y, Jones KF, Lee DR, Kickner SS, Saville BM, Lauzon M, McIntyre A, Honeychurch KM, Jordan R, Hruby DE, Leeds JM.

PLoS One. 2011;6(8):e23237. doi: 10.1371/journal.pone.0023237. Epub 2011 Aug 15.

8.

Evaluation of Lassa antiviral compound ST-193 in a guinea pig model.

Cashman KA, Smith MA, Twenhafel NA, Larson RA, Jones KF, Allen RD 3rd, Dai D, Chinsangaram J, Bolken TC, Hruby DE, Amberg SM, Hensley LE, Guttieri MC.

Antiviral Res. 2011 Apr;90(1):70-9. doi: 10.1016/j.antiviral.2011.02.012. Epub 2011 Mar 1.

9.

Impact of ST-246® on ACAM2000™ smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice.

Berhanu A, King DS, Mosier S, Jordan R, Jones KF, Hruby DE, Grosenbach DW.

Vaccine. 2010 Dec 16;29(2):289-303. doi: 10.1016/j.vaccine.2010.10.039. Epub 2010 Oct 29.

10.

Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.

Jordan R, Chinsangaram J, Bolken TC, Tyavanagimatt SR, Tien D, Jones KF, Frimm A, Corrado ML, Pickens M, Landis P, Clarke J, Marbury TC, Hruby DE.

Antimicrob Agents Chemother. 2010 Jun;54(6):2560-6. doi: 10.1128/AAC.01689-09. Epub 2010 Apr 12.

11.

Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice.

Grosenbach DW, Berhanu A, King DS, Mosier S, Jones KF, Jordan RA, Bolken TC, Hruby DE.

Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):838-43. doi: 10.1073/pnas.0912134107. Epub 2009 Dec 22.

12.

ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.

Berhanu A, King DS, Mosier S, Jordan R, Jones KF, Hruby DE, Grosenbach DW.

Antimicrob Agents Chemother. 2009 Dec;53(12):4999-5009. doi: 10.1128/AAC.00678-09. Epub 2009 Sep 14.

13.

Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor.

Jordan R, Tien D, Bolken TC, Jones KF, Tyavanagimatt SR, Strasser J, Frimm A, Corrado ML, Strome PG, Hruby DE.

Antimicrob Agents Chemother. 2008 May;52(5):1721-7. doi: 10.1128/AAC.01303-07. Epub 2008 Mar 3.

14.

Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination.

Grosenbach DW, Jordan R, King DS, Berhanu A, Warren TK, Kirkwood-Watts DL, Tyavanagimatt S, Tan Y, Wilson RL, Jones KF, Hruby DE.

Vaccine. 2008 Feb 13;26(7):933-46. doi: 10.1016/j.vaccine.2007.11.095. Epub 2007 Dec 26.

15.

Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.

Berhanu A, Wilson RL, Kirkwood-Watts DL, King DS, Warren TK, Lund SA, Brown LL, Krupkin AK, Vandermay E, Weimers W, Honeychurch KM, Grosenbach DW, Jones KF, Hruby DE.

J Virol. 2008 Apr;82(7):3517-29. doi: 10.1128/JVI.01854-07. Epub 2008 Jan 16.

16.
17.

Listeria monocytogenes 10403S HtrA is necessary for resistance to cellular stress and virulence.

Wilson RL, Brown LL, Kirkwood-Watts D, Warren TK, Lund SA, King DS, Jones KF, Hruby DE.

Infect Immun. 2006 Jan;74(1):765-8.

18.

Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses.

Bolken TC, Laquerre S, Zhang Y, Bailey TR, Pevear DC, Kickner SS, Sperzel LE, Jones KF, Warren TK, Amanda Lund S, Kirkwood-Watts DL, King DS, Shurtleff AC, Guttieri MC, Deng Y, Bleam M, Hruby DE.

Antiviral Res. 2006 Feb;69(2):86-97. Epub 2005 Nov 28.

PMID:
16343651
20.
22.

What do physician recommendations of health plans mean?

Wholey DR, Christianson JB, Jones KF, Finch M; Physicians Evaluating Health Plans Research Team.

Am J Manag Care. 2003 Jun;9 Spec No 2:SP88-99.

23.

Statistical analysis of inappropriate results from current Hb screening methods for blood donors.

James V, Jones KF, Turner EM, Sokol RJ.

Transfusion. 2003 Mar;43(3):400-4.

PMID:
12675728
24.

Student questions Resolution 19.

Jones KF.

WMJ. 2002;101(4):4-5. No abstract available.

PMID:
12152515
25.

Biological consequences of antigen and cytokine co-expression by recombinant Streptococcus gordonii vaccine vectors.

Byrd CM, Bolken TC, Jones KF, Warren TK, Vella AT, McDonald J, King D, Blackwood Z, Hruby DE.

Vaccine. 2002 May 22;20(17-18):2197-205.

PMID:
12009273
26.

Analysis of factors affecting surface expression and immunogenicity of recombinant proteins expressed by gram-positive commensal vectors.

Bolken TC, Franke CA, Jones KF, Bell RH, Swanson RM, King DS, Fischetti VA, Hruby DE.

Infect Immun. 2002 May;70(5):2487-91.

27.
28.

Inactivation of the srtA gene in Streptococcus gordonii inhibits cell wall anchoring of surface proteins and decreases in vitro and in vivo adhesion.

Bolken TC, Franke CA, Jones KF, Zeller GO, Jones CH, Dutton EK, Hruby DE.

Infect Immun. 2001 Jan;69(1):75-80.

30.
31.
32.
33.

Update in pediatric dentistry.

Jones KF, Berg JH, Coody D.

J Pediatr Health Care. 1994 Jul-Aug;8(4):160-7.

PMID:
8040797
34.

Fluoride supplementation. A survey of pediatricians and pediatric dentists.

Jones KF, Berg JH.

Am J Dis Child. 1992 Dec;146(12):1488-91.

PMID:
1456266
35.

Analgesic efficacy of bromfenac, ibuprofen, and aspirin in postoperative oral surgery pain.

Forbes JA, Beaver WT, Jones KF, Edquist IA, Gongloff CM, Smith WK, Smith FG, Schwartz MK.

Clin Pharmacol Ther. 1992 Mar;51(3):343-52.

PMID:
1544291
36.

Genetic diversity among the T-protein genes of group A streptococci.

Jones KF, Schneewind O, Koomey JM, Fischetti VA.

Mol Microbiol. 1991 Dec;5(12):2947-52.

PMID:
1809837
37.

Effect of caffeine on ibuprofen analgesia in postoperative oral surgery pain.

Forbes JA, Beaver WT, Jones KF, Kehm CJ, Smith WK, Gongloff CM, Zeleznock JR, Smith JW.

Clin Pharmacol Ther. 1991 Jun;49(6):674-84.

PMID:
2060256
38.
39.

Microleakage of interim endodontic filling materials.

Jones KF, Fruithandler RC, Berg JH.

Am J Dent. 1990 Apr;3(2):71-4.

PMID:
2076227
40.

Evaluation of aspirin, caffeine, and their combination in postoperative oral surgery pain.

Forbes JA, Jones KF, Kehm CJ, Smith WK, Gongloff CM, Zeleznock JR, Smith JW, Beaver WT, Kroesen M.

Pharmacotherapy. 1990;10(6):387-93.

PMID:
2287558
41.
42.

Spontaneous M6 protein size mutants of group A streptococci display variation in antigenic and opsonogenic epitopes.

Jones KF, Hollingshead SK, Scott JR, Fischetti VA.

Proc Natl Acad Sci U S A. 1988 Nov;85(21):8271-5.

43.

Structure, function, and genetics of streptococcal M protein.

Fischetti VA, Jones KF, Hollingshead SK, Scott JR.

Rev Infect Dis. 1988 Jul-Aug;10 Suppl 2:S356-9. Review.

PMID:
3055203
46.

Streptococcal M protein size mutants occur at high frequency within a single strain.

Fischetti VA, Jarymowycz M, Jones KF, Scott JR.

J Exp Med. 1986 Oct 1;164(4):971-80.

47.

Immunochemical localization and amino acid sequences of crossreactive epitopes within the group A streptococcal M6 protein.

Jones KF, Khan SA, Erickson BW, Hollingshead SK, Scott JR, Fischetti VA.

J Exp Med. 1986 Oct 1;164(4):1226-38.

48.
49.

Size variation of the M protein in group A streptococci.

Fischetti VA, Jones KF, Scott JR.

J Exp Med. 1985 Jun 1;161(6):1384-401.

50.

Location of variable and conserved epitopes among the multiple serotypes of streptococcal M protein.

Jones KF, Manjula BN, Johnston KH, Hollingshead SK, Scott JR, Fischetti VA.

J Exp Med. 1985 Mar 1;161(3):623-8.

Supplemental Content

Loading ...
Support Center